

Dr. Nancy Cole, née Simonian (Dr. Nancy Simonian), Cambridge, USA

Born on December 14, 1960, in Lake Forest, USA

US citizen



Independent Consultant

- 1983 Bachelor's degree in biology from Princeton University, USA
- 1988 M.D. degree from University of Pennsylvania, USA
- 1988 – 1989 Intern Internal Medicine at Massachusetts General Hospital, USA
- 1989 – 1992 Resident Neurology at Massachusetts General Hospital, USA
- 1992 – 1994 Assistant Professor and Instructor of Neurology at Harvard Medical School, USA
- 1995 – 1997 Associate Director of Medical Research at Biogen, Inc., USA
- 1997 – 2000 Director of Medical Research at Biogen, Inc., USA
- 2000 – 2001 Senior Director of Medical Research at Biogen, Inc., USA
- 2001 Vice President of Medical Research and Development at Biogen, Inc., USA
- 2001 – 2003 Vice President of Clinical Development at Millenium Pharmaceuticals, Inc., USA
- 2003 – 2005 Senior Vice President of Clinical Development at Millenium Pharmaceuticals, Inc., USA
- 2005 – 2006 Senior Vice President of Clinical, Medical and Regulatory Affairs at Millenium Pharmaceuticals, Inc., USA
- 2006 – 2011 Chief Medical Officer at Millenium Pharmaceuticals, Inc. (since 2008 Millennium: The Takeda Oncology Company), USA
- 2012 – 2023 Chief Executive Officer at Syros Pharmaceuticals, Inc., USA

Membership on statutory supervisory boards:

- none

Memberships in comparable supervising bodies of German or foreign corporations:

- Alltrna, Inc. (non-executive member of the Board of Directors)
- Syros Pharmaceuticals, Inc. (non-executive member of the Board of Directors, listed company)

Dr. Nancy Simonian does not perform other significant activities.

In addition to her international business experience, Dr. Nancy Simonian will support the work of the Supervisory Board in particular through the expertise and experience she possesses in the fields of

research and development, healthcare, finance, controlling and risk management, as well as human resources. Her expertise and experience are based on knowledge gained in part through her previous work at US based pharmaceutical companies, in particular in roles with increasing responsibilities, lastly as Chief Medical Officer, at Millenium Pharmaceuticals and as longtime CEO at Syros Pharmaceuticals as well as member of the Board of Directors of other companies.

The Supervisory Board has satisfied itself that Dr. Nancy Simonian is able to meet the expected time commitments for performing her Supervisory Board duties, taking into account her seats on other boards.

The Supervisory Board regards Dr. Nancy Simonian as independent. The Supervisory Board does not consider there to be any personal or business relationships between Dr. Nancy Simonian on the one hand and the companies of the Bayer Group, the governance bodies of Bayer Aktiengesellschaft, or any stockholder that directly or indirectly holds more than 10 percent of the voting shares of Bayer Aktiengesellschaft on the other, that are of material significance to the decision of the Stockholders' Meeting regarding her election.